StonvexLoading…
StonvexStonvexStonvexCore line items from EPSN's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $51.59M | $31.52M | $30.73M | $69.96M |
Operating Income | $-10.52M | $3.42M | $5.42M | $46.97M |
Net Income | $-5.80M | $1.93M | $6.95M | $35.35M |
EPS (Diluted) | $-0.25 | $0.09 | $0.31 | $1.51 |
Total Assets | $228.24M | $120.45M | $124.04M | $123.86M |
Total Liabilities | $103.51M | $23.73M | $23.43M | $19.62M |
Cash & Equivalents | $8.96M | $6.52M | $13.40M | $45.24M |
Free Cash Flow OCF − CapEx | Not available | Not available | Not available | Not available |
Shares Outstanding | 30.24M | 22.01M | 22.15M | 23.12M |